Last mentioned: Feb 19, 2026
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
This page surfaces every story mentioning Jan van de Winkel across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Jan van de Winkel was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |